Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting
Provided By GlobeNewswire
Last update: May 27, 2025
CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading live biotherapeutics company, today announced the Company will be presenting new exploratory biomarker data from its SER-155 Phase 1b study in a poster session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 –June 3 in Chicago.
Read more at globenewswire.com
